APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Solid Tumor Drug Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchSolid Tumor Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Tumor Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Solid Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Tumor Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Tumor Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Solid Tumor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Solid Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Solid Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Solid Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Solid Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Solid Tumor Drug include Johnson & Johnson, Pfizer Inc, GlaxoSmithKline plc., Baxter, AstraZeneca, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Celgene Corporation and Bristol-Myers Squibb Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Solid Tumor Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Solid Tumor Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Solid Tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Solid Tumor Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Solid Tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Solid Tumor Drug revenue, projected growth trends, production technology, application and end-user industry.

Solid Tumor Drug Segment by Company

Johnson & Johnson

Pfizer Inc

GlaxoSmithKline plc.

Baxter

AstraZeneca

F. Hoffmann-La Roche Ltd.

Eli Lilly and Company

Celgene Corporation

Bristol-Myers Squibb Company

Biogen

Amgen Limited & Amgen Ireland Limited

Abbott Laboratories

Solid Tumor Drug Segment by Type

Small Molecules

Biologics

Solid Tumor Drug Segment by Application

Radiology

Neurology

Oncology

Others

Solid Tumor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Solid Tumor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Solid Tumor Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Solid Tumor Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Solid Tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Small Molecules Major Player Table 3. Biologics Major Player Table 4. Global Solid Tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Radiology Major Player Table 6. Neurology Major Player Table 7. Oncology Major Player Table 8. Others Major Player Table 9. Solid Tumor Drug Industry Trends Table 10. Solid Tumor Drug Industry Drivers Table 11. Solid Tumor Drug Industry Opportunities and Challenges Table 12. Solid Tumor Drug Industry Restraints Table 13. Global Solid Tumor Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Solid Tumor Drug Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Solid Tumor Drug Market Share by Region (2021-2026) Table 16. Global Solid Tumor Drug Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Solid Tumor Drug Market Share by Region (2027-2032) Table 18. Global Solid Tumor Drug Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Solid Tumor Drug Revenue Market Share by Players (2021-2026) Table 20. Global Solid Tumor Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Solid Tumor Drug Key Players Headquarters & Area Served Table 22. Global Solid Tumor Drug Players, Product Type & Application Table 23. Global Solid Tumor Drug Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Solid Tumor Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Solid Tumor Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Solid Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Solid Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Solid Tumor Drug Revenue Market Share by Type (2021-2026) Table 30. Global Solid Tumor Drug Revenue Market Share by Type (2027-2032) Table 31. Global Solid Tumor Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Solid Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Solid Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Solid Tumor Drug Revenue Market Share by Application (2021-2026) Table 35. Global Solid Tumor Drug Revenue Market Share by Application (2027-2032) Table 36. Johnson & Johnson Company Information Table 37. Johnson & Johnson Business Overview Table 38. Johnson & Johnson Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Johnson & Johnson Solid Tumor Drug Product Portfolio Table 40. Johnson & Johnson Recent Development Table 41. Pfizer Inc Company Information Table 42. Pfizer Inc Business Overview Table 43. Pfizer Inc Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Pfizer Inc Solid Tumor Drug Product Portfolio Table 45. Pfizer Inc Recent Development Table 46. GlaxoSmithKline plc. Company Information Table 47. GlaxoSmithKline plc. Business Overview Table 48. GlaxoSmithKline plc. Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio Table 50. GlaxoSmithKline plc. Recent Development Table 51. Baxter Company Information Table 52. Baxter Business Overview Table 53. Baxter Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Baxter Solid Tumor Drug Product Portfolio Table 55. Baxter Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca Solid Tumor Drug Product Portfolio Table 60. AstraZeneca Recent Development Table 61. F. Hoffmann-La Roche Ltd. Company Information Table 62. F. Hoffmann-La Roche Ltd. Business Overview Table 63. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio Table 65. F. Hoffmann-La Roche Ltd. Recent Development Table 66. Eli Lilly and Company Company Information Table 67. Eli Lilly and Company Business Overview Table 68. Eli Lilly and Company Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Eli Lilly and Company Solid Tumor Drug Product Portfolio Table 70. Eli Lilly and Company Recent Development Table 71. Celgene Corporation Company Information Table 72. Celgene Corporation Business Overview Table 73. Celgene Corporation Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Celgene Corporation Solid Tumor Drug Product Portfolio Table 75. Celgene Corporation Recent Development Table 76. Bristol-Myers Squibb Company Company Information Table 77. Bristol-Myers Squibb Company Business Overview Table 78. Bristol-Myers Squibb Company Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio Table 80. Bristol-Myers Squibb Company Recent Development Table 81. Biogen Company Information Table 82. Biogen Business Overview Table 83. Biogen Solid Tumor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Biogen Solid Tumor Drug Product Portfolio Table 85. Biogen Recent Development Table 86. Amgen Limited & Amgen Ireland Limited Company Information Table 87. Amgen Limited & Amgen Ireland Limited Business Overview Table 88. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio Table 90. Amgen Limited & Amgen Ireland Limited Recent Development Table 91. Abbott Laboratories Company Information Table 92. Abbott Laboratories Business Overview Table 93. Abbott Laboratories Solid Tumor Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Abbott Laboratories Solid Tumor Drug Product Portfolio Table 95. Abbott Laboratories Recent Development Table 96. North America Solid Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Solid Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Solid Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Solid Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Solid Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Solid Tumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Solid Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Solid Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Solid Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Solid Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Solid Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Solid Tumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 110. China Solid Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 111. China Solid Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 112. China Solid Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 113. China Solid Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Solid Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Solid Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Solid Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Solid Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Solid Tumor Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Solid Tumor Drug Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Solid Tumor Drug Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Solid Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Solid Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Solid Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Solid Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Solid Tumor Drug Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Solid Tumor Drug Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Solid Tumor Drug Image Figure 2. Global Solid Tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Small Molecules Image Figure 5. Biologics Image Figure 6. Global Solid Tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Solid Tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Radiology Image Figure 9. Neurology Image Figure 10. Oncology Image Figure 11. Others Image Figure 12. Global Solid Tumor Drug Market Size (US$ Million) & (2021-2032) Figure 13. Global Solid Tumor Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Solid Tumor Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Solid Tumor Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Solid Tumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Solid Tumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Solid Tumor Drug Revenue Market Share by Type (2021-2032) Figure 20. Global Solid Tumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Solid Tumor Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Solid Tumor Drug Revenue Market Share by Application (2021-2032) Figure 23. North America Solid Tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Solid Tumor Drug Revenue Share by Type (2021-2032) Figure 25. North America Solid Tumor Drug Revenue Share by Application (2021-2032) Figure 26. North America Solid Tumor Drug Revenue Share by Country (2021-2032) Figure 27. United States Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Solid Tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Solid Tumor Drug Revenue Share by Type (2021-2032) Figure 32. Europe Solid Tumor Drug Revenue Share by Application (2021-2032) Figure 33. Europe Solid Tumor Drug Revenue Share by Country (2021-2032) Figure 34. Germany Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Solid Tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Solid Tumor Drug Revenue Share by Type (2021-2032) Figure 44. China Solid Tumor Drug Revenue Share by Application (2021-2032) Figure 45. Asia Solid Tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Solid Tumor Drug Revenue Share by Type (2021-2032) Figure 47. Asia Solid Tumor Drug Revenue Share by Application (2021-2032) Figure 48. Asia Solid Tumor Drug Revenue Share by Region (2021-2032) Figure 49. Japan Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Solid Tumor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Solid Tumor Drug Revenue Share by Type (2021-2032) Figure 57. SAMEA Solid Tumor Drug Revenue Share by Application (2021-2032) Figure 58. SAMEA Solid Tumor Drug Revenue Share by Country (2021-2032) Figure 59. Brazil Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Solid Tumor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Radiology
  • Neurology
  • Oncology
  • Others
Companies covered
  • Johnson & Johnson
  • Pfizer Inc
  • GlaxoSmithKline plc.
  • Baxter
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Eli Lilly and Company
  • Celgene Corporation
  • Bristol-Myers Squibb Company
  • Biogen
  • Amgen Limited & Amgen Ireland Limited
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Solid Tumor Drug Market by Type
  3. 1.2.1 Global Solid Tumor Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecules
  5. 1.2.3 Biologics
  6. 1.3 Solid Tumor Drug Market by Application
  7. 1.3.1 Global Solid Tumor Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Radiology
  9. 1.3.3 Neurology
  10. 1.3.4 Oncology
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Solid Tumor Drug Market Dynamics
  1. 2.1 Solid Tumor Drug Industry Trends
  2. 2.2 Solid Tumor Drug Industry Drivers
  3. 2.3 Solid Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Solid Tumor Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Solid Tumor Drug Market Perspective (2021-2032)
  2. 3.2 Global Solid Tumor Drug Growth Trends by Region
  3. 3.2.1 Global Solid Tumor Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Solid Tumor Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Solid Tumor Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Solid Tumor Drug Revenue by Players
  2. 4.1.1 Global Solid Tumor Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Solid Tumor Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Solid Tumor Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Solid Tumor Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Solid Tumor Drug Key Players Headquarters & Area Served
  7. 4.4 Global Solid Tumor Drug Players, Product Type & Application
  8. 4.5 Global Solid Tumor Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Solid Tumor Drug Market CR5 and HHI
  11. 4.6.3 2025 Solid Tumor Drug Tier 1, Tier 2, and Tier 3
5 Solid Tumor Drug Market Size by Type
  1. 5.1 Global Solid Tumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Solid Tumor Drug Revenue by Type (2021-2032)
  3. 5.3 Global Solid Tumor Drug Revenue Market Share by Type (2021-2032)
6 Solid Tumor Drug Market Size by Application
  1. 6.1 Global Solid Tumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Solid Tumor Drug Revenue by Application (2021-2032)
  3. 6.3 Global Solid Tumor Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Solid Tumor Drug Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Pfizer Inc
  8. 7.2.1 Pfizer Inc Company Information
  9. 7.2.2 Pfizer Inc Business Overview
  10. 7.2.3 Pfizer Inc Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Inc Solid Tumor Drug Product Portfolio
  12. 7.2.5 Pfizer Inc Recent Developments
  13. 7.3 GlaxoSmithKline plc.
  14. 7.3.1 GlaxoSmithKline plc. Company Information
  15. 7.3.2 GlaxoSmithKline plc. Business Overview
  16. 7.3.3 GlaxoSmithKline plc. Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolio
  18. 7.3.5 GlaxoSmithKline plc. Recent Developments
  19. 7.4 Baxter
  20. 7.4.1 Baxter Company Information
  21. 7.4.2 Baxter Business Overview
  22. 7.4.3 Baxter Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Baxter Solid Tumor Drug Product Portfolio
  24. 7.4.5 Baxter Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Solid Tumor Drug Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 F. Hoffmann-La Roche Ltd.
  32. 7.6.1 F. Hoffmann-La Roche Ltd. Company Information
  33. 7.6.2 F. Hoffmann-La Roche Ltd. Business Overview
  34. 7.6.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolio
  36. 7.6.5 F. Hoffmann-La Roche Ltd. Recent Developments
  37. 7.7 Eli Lilly and Company
  38. 7.7.1 Eli Lilly and Company Company Information
  39. 7.7.2 Eli Lilly and Company Business Overview
  40. 7.7.3 Eli Lilly and Company Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly and Company Solid Tumor Drug Product Portfolio
  42. 7.7.5 Eli Lilly and Company Recent Developments
  43. 7.8 Celgene Corporation
  44. 7.8.1 Celgene Corporation Company Information
  45. 7.8.2 Celgene Corporation Business Overview
  46. 7.8.3 Celgene Corporation Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Celgene Corporation Solid Tumor Drug Product Portfolio
  48. 7.8.5 Celgene Corporation Recent Developments
  49. 7.9 Bristol-Myers Squibb Company
  50. 7.9.1 Bristol-Myers Squibb Company Company Information
  51. 7.9.2 Bristol-Myers Squibb Company Business Overview
  52. 7.9.3 Bristol-Myers Squibb Company Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolio
  54. 7.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 7.10 Biogen
  56. 7.10.1 Biogen Company Information
  57. 7.10.2 Biogen Business Overview
  58. 7.10.3 Biogen Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Biogen Solid Tumor Drug Product Portfolio
  60. 7.10.5 Biogen Recent Developments
  61. 7.11 Amgen Limited & Amgen Ireland Limited
  62. 7.11.1 Amgen Limited & Amgen Ireland Limited Company Information
  63. 7.11.2 Amgen Limited & Amgen Ireland Limited Business Overview
  64. 7.11.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolio
  66. 7.11.5 Amgen Limited & Amgen Ireland Limited Recent Developments
  67. 7.12 Abbott Laboratories
  68. 7.12.1 Abbott Laboratories Company Information
  69. 7.12.2 Abbott Laboratories Business Overview
  70. 7.12.3 Abbott Laboratories Solid Tumor Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Abbott Laboratories Solid Tumor Drug Product Portfolio
  72. 7.12.5 Abbott Laboratories Recent Developments
8 North America
  1. 8.1 North America Solid Tumor Drug Revenue (2021-2032)
  2. 8.2 North America Solid Tumor Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Solid Tumor Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Solid Tumor Drug Revenue by Type (2027-2032)
  5. 8.3 North America Solid Tumor Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Solid Tumor Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Solid Tumor Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Solid Tumor Drug Revenue by Application (2027-2032)
  9. 8.5 North America Solid Tumor Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Solid Tumor Drug Revenue by Country
  11. 8.6.1 North America Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Solid Tumor Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Solid Tumor Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Solid Tumor Drug Revenue (2021-2032)
  2. 9.2 Europe Solid Tumor Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Solid Tumor Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Solid Tumor Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Solid Tumor Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Solid Tumor Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Solid Tumor Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Solid Tumor Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Solid Tumor Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Solid Tumor Drug Revenue by Country
  11. 9.6.1 Europe Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Solid Tumor Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Solid Tumor Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Solid Tumor Drug Revenue (2021-2032)
  2. 10.2 China Solid Tumor Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Solid Tumor Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Solid Tumor Drug Revenue by Type (2027-2032)
  5. 10.3 China Solid Tumor Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Solid Tumor Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Solid Tumor Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Solid Tumor Drug Revenue by Application (2027-2032)
  9. 10.5 China Solid Tumor Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Solid Tumor Drug Revenue (2021-2032)
  2. 11.2 Asia Solid Tumor Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Solid Tumor Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Solid Tumor Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Solid Tumor Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Solid Tumor Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Solid Tumor Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Solid Tumor Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Solid Tumor Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Solid Tumor Drug Revenue by Country
  11. 11.6.1 Asia Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Solid Tumor Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Solid Tumor Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Solid Tumor Drug Revenue (2021-2032)
  2. 12.2 SAMEA Solid Tumor Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Solid Tumor Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Solid Tumor Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Solid Tumor Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Solid Tumor Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Solid Tumor Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Solid Tumor Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Solid Tumor Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Solid Tumor Drug Revenue by Country
  11. 12.6.1 SAMEA Solid Tumor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Solid Tumor Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Solid Tumor Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst